No Data
No Data
Jumpcode Genomics and Takara Bio USA Announce Global Patent Partnership
Cutting-edge technologies with potential to transform molecular biology Jumpcode Genomics, a genome technology platform company focused on improving the understanding of human biology, and Takara Bio USA, Inc.
Convertible Stock List (Part 2) [Parabolic Signal Convertible Stock List]
○ List of sales conversion stocks market code stock name closing price SAR Tokyo Stock Exchange Prime <1333> Maruha Nichiro 3273 3367 <1515> Nippon Steel Mining 5100 5860 <1662> Petroleum Resources 6630 6960 <1820> Nishimatsu Ken 4420 4720 <1871> PS Mitsubishi
Sanyo Kasei --- Starts selling “EXORPTION (R),” an extracellular vesicle (EV) purification kit such as exosomes
Sanyo Chemical Industries (4471) announced on the 13th that it will start selling “EXORPTION (R).” “EXORPTION (R)” is a purification kit that can recover extracellular vesicles (EVs) such as exosomes in a short time with high purity and high yield with simple operation. Sales of this kit began in 2024/5 through Cosmo Bio <3386> and Takara Bio <4974>. “EXORPTION (R)” is a special hydrogel bee that absorbs body fluids
Lightworkers, landowners, etc. (additional) Rating
Target Stock Price Change Code | Stock Name | Securities Company | Conventional | After Change |------|---------------|-------------|-------------|---------|<1926>|Light Engineering | Nomura | 2050 yen | 2300 yen |<2327>|NSSOL |SMBC Nikko | 4000 yen | 4700 yen |<3092>|ZOZO
Honda's 24/3 operating profit increased 77.0% to 1,381.9 billion yen, 25/3 forecast 2.8% increase to 1.42 trillion yen
The financial results for the fiscal year ending 2024/3 announced by Honda <7267> were sales revenue of 20.428.82 billion yen, up 20.8% from the previous fiscal year, and operating profit of 1,381.97 billion yen, up 77% from the same period. In addition to growing sales in North America, which is the main market, and strong hybrid cars, the depreciation of the yen also contributed. At the same time, a stock buyback with an upper limit of 300 billion yen was also announced. Note that for the fiscal year ending 2025/3, sales revenue decreased 0.6% from the previous fiscal year to 20.3 trillion yen, and operating profit increased 2.8% to 1.4 trillion yen
Pursue high-growth companies! Fiscal Year Ending 25/3 [Increase in Sales and Profit] List <Special Feature on Growth Stocks> 5/10 Edition
As financial results announcements for the fiscal year ending March 31, '24 are in full swing, market attention is focused on the earnings forecast for the fiscal year ending 25/3, which will be announced at the same time. Demand for semiconductors is expected to recover this fiscal year, and it seems that there are many views that the upward trend in profit will continue, as domestic demand-related expansion is also expected against the backdrop of the penetration of price increases and an increase in inbound consumption due to depreciation of the yen. There is also growing interest in movements to strengthen shareholder returns aimed at improving capital efficiency. Increase for the fiscal year ending 25/3 from the financial results announced today in this special issue
No Data